



Wall Marjama

An Intellectual Property Practice

250 South Clinton Street, Suite 300
Syracuse, New York 13202
Telephone: 315-425-9000
Facsimile: 315-425-9114

RECEIVED
CENTRAL FAX CENTER
NOV. 01 2006

FACSIMILE TRANSMISSION

To: Office of Initial Patent Examination's Filing Receipt Corrections

Facsimile No: 571-273-8300

From: Jessica LaCelle

Date: October 31, 2006

Re: Request a corrected Filing Receipt

Pages: 3 (*including cover page*)

Comments: The title of the invention is incorrect. It should read as:
"BIOSENSOR AND BLOOD COMPONENT
ANALYTICAL METHOD"

IMPORTANT - THIS MESSAGE IS INTENDED ONLY FOR THE USE OF THE INDIVIDUAL OR ENTITY TO WHICH IT IS ADDRESSED, AND MAY CONTAIN INFORMATION THAT IS PRIVILEGED, CONFIDENTIAL AND EXEMPT FROM DISCLOSURE UNDER APPLICABLE LAW. IF THE READER OF THIS MESSAGE IS NOT THE INTENDED RECIPIENT, OR THE EMPLOYEE OR AGENT RESPONSIBLE TO DELIVER IT TO THE INTENDED RECIPIENT, YOU ARE HEREBY NOTIFIED THAT READING, DISSEMINATING, DISTRIBUTING OR COPYING THIS COMMUNICATION IS STRICTLY PROHIBITED. IF YOU HAVE RECEIVED THIS COMMUNICATION IN ERROR, PLEASE IMMEDIATELY NOTIFY US BY TELEPHONE, AND DESTROY THE COMMUNICATION. THANK YOU.

Wall Marjama & Bilinski LLP
Offices in New York & Massachusetts • www.wallmarjama.com

PAGE 1/3 * RCVD AT 11/1/2006 10:04:24 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/1 * DNI:2738300 * CSID:3154259114 * DURATION (mm:ss):01:46

BEST AVAILABLE COPY

NOV-01-06 10:51AM FROM-WALL,MARJAMA & BILINSKI

3154259114

RECEIVED
T-173 P-002/003 F-094
CENTRAL FAX CENTER



UNITED STATES PATENT AND TRADEMARK OFFICE

NOV 01 2006

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE RECD	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
10/049,366	05/10/2002	1623	1272	967-026	6	34	3

Wall Marjama & Bilinski
Suite 400
101 South Salina Street
Syracuse, NY 13202

CONFIRMATION NO. 1103

FILING RECEIPT



OC000000008214875

Date Mailed: 06/03/2002

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Filing Receipt Corrections, facsimile number 703-746-9195. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Mie Takahashi, Ehime, JAPAN;
Masataka Nadaoka, Ehime, JAPAN;
Hirotaka Tanaka, Ehime, JAPAN;
Fumihisa Kitawaki, Osaka, JAPAN;

Domestic Priority data as claimed by applicant

THIS APPLICATION IS A 371 OF PCT/JP01/04649 06/01/2001

Foreign Applications

JAPAN 2000-164990 06/01/2000

Projected Publication Date: 09/12/2002

Non-Publication Request: No

Early Publication Request: No

Title

Biosensor and blood component analyzing method

Preliminary Class

Analytical

blood analyzing

PAGE 2/3 * RCVD AT 11/1/2006 10:04:24 AM [Eastern Standard Time] * SVR:USPTO-EFXRF-5/1 * DNI:2738300 * CSID:3154259114 * DURATION (mm:ss):0146

BEST AVAILABLE COPY

NOV-01-06

10:52AM

FROM-WALL,MARJAMA & BILINSKI

3154259114

T-273 P.003/003 F-094

Page 2 of 2

435

**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier license has been issued under 37 CFR 5.15(b). The license is subject to revocation upon written notification. The date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related application(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).